drugset / Trial / NCT05983094
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
Phase 2
Not yet recruiting
181 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center · collabChinese Academy of Medical Sciences · collabFirst Hospital of China Medical University · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to evaluate the efficacy and safety of Utidelone based regimen as neoadjuvant treatment With High-risk Early-stage or Locally Advanced Breast Cancer.
Timeline
- Start
- 2023-09-01
- Primary completion
- 2026-09-01
- Completion
- 2027-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Epirubicin | Small molecule | 75 mg/m2 | — |
| Subject | Epothilone D | Small molecule | 30 mg/m2 | — |
| Subject | Pertuzumab | Monoclonal antibody | 420 mg/kg | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |